An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists

Abstract

For a subset of DMARD-drug combinations, rheumatologists and clinical pharmacists differed in their assessments of clinical relevance.

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

“…It is considered that HCQ may be safe for nursing mothers with RA, especially compared with alternatives such as methotrexate or leflunomide (Sammaritano and Bermas 2014). The relative amounts of HCQ that appear in neonatal blood are in the micromolar range (Van Roon et al 2009). This may not be of toxicological significance, although data in laboratory animals on the feto-toxic actions of HCQ and CQ are lacking.…”

“…Among the potentially important significant drug-drug interactions involving HCQ and CQ, with antibiotics, aspirin, paracetamol, cholestyramine, proton-pump inhibitors or H 2 receptor antagonists, imipramine, methotrexate, cyclosporine, caffeine, debrisoquine, metoprolol, and other anti-parasitic agents have received particular attention because of the potential for microsomal P450 interactions or impact on hepato-renal clearance (Gupta et al 1979;Ali 1985;Ette et al 1987a, b;McElnay et al 1985;Gendrel et al 1990;Kull and Besterman 1990;Onyeji et al 1993;Raina et al 1993;Bannwarth et al 1996;Adedoyin et al 1998;van den Borne et al 1998;Oforah and Anyogo 2000;Somer et al 2000;Vezmar and Georges 2000;Carmichael et al 2002;Alisky et al 2006;Cook et al 2006;Ilo et al, 2006Ilo et al, , 2008Obua et al 2006;Skinner-Adams et al 2007;Namazi 2009;Van Roon et al 2009). …”

Medikamentöse Interaktionen in der Rheumatologie

“…Für alle heute verwendeten synthetischen Disease-modifying anti-rheumatic drugs (sDMARD) sind Interaktionen berichtet (Übersicht bei [8]). In vielen Fällen ist die praktische Relevanz aber fraglich; einen Überblick gibt .…”

P2X Receptors as New Therapeutic Targets

“…This study is prior to patient studies. Since patients with rheumatoid arthritis receive multiple co-medications, that might be taken a risk of the co-morbid conditions, it is necessary to evaluate the potential of RA drug candidates to perpetrate a drug-drug interaction (DDI) with methotrexate which is a most commonly drug treating RA (van Roon et al 2009). Methotrexate is a substrate of the human transporters OAT1, OAT3, MRP2 and BCRP which all-mediate active renal elimination.…”